Emerging therapeutic uses of direct‐acting oral anticoagulants: An evidence‐based perspective

@article{Raschi2017EmergingTU,
  title={Emerging therapeutic uses of direct‐acting oral anticoagulants: An evidence‐based perspective},
  author={E. Raschi and M. Bianchin and R. De Ponti and F. De Ponti and W. Ageno},
  journal={Pharmacological Research},
  year={2017},
  volume={120},
  pages={206–218}
}
  • E. Raschi, M. Bianchin, +2 authors W. Ageno
  • Published 2017
  • Medicine
  • Pharmacological Research
  • &NA; Direct‐acting oral anticoagulants (DOACs) were claimed to cause a potential paradigm shift in the therapeutic scenario of patients requiring short‐ and long‐term anticoagulation, by virtue of their pharmacological properties, perceived as innovative. The evidence gathered so far (from pre‐approval pivotal trials to real‐world post‐marketing observational data) consistently confirmed that DOACs are overall comparable to vitamin‐K antagonists (VKAs) in terms of safety, efficacy and… CONTINUE READING
    9 Citations
    Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?
    • 4
    Pharmacokinetic drug interactions of the non‐vitamin K antagonist oral anticoagulants (NOACs)
    • 29
    ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations
    • 12
    Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation
    • 6
    The ups and downs of anticoagulation prescription in the United Kingdom
    • 1

    References

    SHOWING 1-10 OF 101 REFERENCES
    Novel oral anticoagulants for heparin-induced thrombocytopenia
    • 22
    Italian intersociety consensus on DOAC use in internal medicine
    • 38
    • PDF